ライブ

FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract Pharma Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times Endpoints NewsParabilis Medicines charts $413M IPO to back peptide pipeline FierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC PharmaVoiceHouse bill aims to crack down on China biotech deals PharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problems FierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’

FierceBiotech 2026年6月4日

From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’

Fierce sat down with Cabaletta's executives at EULAR to discuss their approval timeline and which areas of development they feel like they have a head start.

Fierce sat down with Cabaletta's executives at EULAR to discuss their approval timeline and which areas of development they feel like they have a head start.